Tag: Leukemia

First approved by the FDA in February 2021, Breyanzi (lisocabtagene maraleucel) is a revolutionary and personalized form of cancer treatment. So, what is the generic name for Breyanzi? It is lisocabtagene maraleucel, a highly specialized and individualized cellular immunotherapy. This therapy is developed for each patient using their own genetically modified immune cells to fight specific blood cancers.

The administration frequency of mitoxantrone varies significantly based on the medical condition it is treating, from quarterly infusions for multiple sclerosis to intensive, multi-day cycles for certain cancers. Understanding **how often is mitoxantrone given** is critical due to its potent nature and potential for serious side effects.

According to the U.S. Food and Drug Administration (FDA), the generic name for Synribo is omacetaxine mepesuccinate. This medication was developed to treat certain forms of chronic myeloid leukemia (CML) in patients who had become resistant to or intolerant of other therapies. It is important to note that Synribo has been permanently discontinued and is no longer available in the U.S. market.

First approved by the FDA in 1987 for acute myeloid leukemia, mitoxantrone is a potent medication used to treat several serious conditions, including aggressive forms of multiple sclerosis and advanced prostate cancer. Due to its significant risk profile, it is typically reserved for cases where other treatments have been ineffective.

Originally approved in the early 2000s, imatinib—often known by brand names like Imanib and Gleevec—revolutionized the treatment landscape for certain cancers. A common question for many patients and caregivers is, **What is Imanib 400 mg used for?** It is a targeted therapy designed to block specific proteins that cause cancer cells to grow and multiply.

Acute Promyelocytic Leukemia (APL) accounts for 5 to 15% of all adult acute myeloid leukemia cases. This article explains what is the use of INJ ATRA, a pivotal medication that has revolutionized APL treatment, leading to remission in 85-90% of patients.

Bestatin, also known as Ubenimex, is a low-molecular-weight dipeptide initially isolated from the bacterium *Streptomyces olivoreticuli* that has been clinically used in Japan and several other countries as an immunomodulatory agent. The medication's 20 mg dosage is primarily explored for its supportive role in oncology, particularly as an adjuvant therapy alongside chemotherapy for certain leukemias and solid tumors.